BRESER Study Demonstrates Real-World Efficacy & Safety of Lupin’s Ranibizumab Biosimilar (Ranieyes) скачать в хорошем качестве

BRESER Study Demonstrates Real-World Efficacy & Safety of Lupin’s Ranibizumab Biosimilar (Ranieyes)

#Ranieyes #Ranibizumab #BRESERstudy Ranieyes is the Ranibizumab Biosimilar which is an Indian Ranibizumab Biosimilar manufactured by Lupin Ltd & approved in India for various indications such as retinal vein occlusion (RVO), neovascular age-related macular degeneration (nAMD), myopic macular neovascularization (MNV), and Diabetic macular edema (DME). Ranieyes is an anti-VEG intravitreal injection that is available in Indian market since 2021. It has been developed as a biosimilar to reference product Lucentis and it has been found to be safe and well tolerated, biosimilarity being demonstrated through quality/analytical & pragmatic clinic trial studies. Recently the BRESER Study, by Dr. Ashish Sharma et. all, has been published in the journal of Vitreo Retinal Diseases, a peer-reviewed journal of the American Society of Retina Specialists (ASRS). BRESER Study is a real-world, multicenter, uncontrolled, observational study across 7 eye care centers in India. A total of 474 ranibizumab biosimilar injections were administered to 268 eyes of 254 patients. The study included patients who received at least one 0.5 mg IVT injection of Ranieyes to evaluate its effectiveness and safety. The treatment was given for diabetic macular edema (DME) (n = 112), macular neovascularization (MNV) (n = 92), retinal vein occlusion (RVO) (n = 54), cystoid macular edema (CME) (n = 4), and proliferative diabetic retinopathy (PDR) with vitreous hemorrhage (n = 6). The mean follow-up duration was 7.7 ± 5.4 weeks. The results revealed findings which include: • Significant improvement in mean logMAR BCVA (Best-Corrected Visual Acuity) (±SD) was observed from baseline to the last follow-up as follows:  In diabetic macular edema (DME) cases, improvement was observed from 0.77 ± 0.37 (6/36) to 0.43 ± 0.25 (6/15)  In macular neovascularization (MNV) cases, improvement was recorded from 0.95 ± 0.53 (6/60) to 0.59 ± 0.42 (6/24)  In retinal vein occlusion (RVO) cases, improvement was noted from 0.83 ± 0.40 (6/45) to 0.44 ± 0.32 (6/15).  In PDR (Proliferative Diabetic Retinopathy) cases with vitreous haemorrhage, mean logMAR BCVA improved from 0.71 ± 0.54 (6/30) to 0.28 ± 0.37 (6/12), though this change was not statistically significant. • Significant reductions in central subfield thickness (CST) were noted:  The CST improved significantly overall (z = −13.3; r = −0.8) and in the DME group (z = −8.3; r = −0.8), MNV group (z = −7.8; r = −0.8), and RVO group.  In eyes with PDR and a vitreous hemorrhage, the overall mean CST at baseline was 341.6 ± 183.7 μm, improving to 229.5 ± 25.3 μm.  In cystoid macular edema (CME) cases, mean CST decreased from 325.5 ± 50.9 μm to 251 ± 65 μm, but the difference was not statistically significant. • The findings of this preliminary real-world study corroborate the clinical efficacy and safety of Ranieyes as a ranibizumab biosimilar across the approved indications, based on clinical evidence. Today we have Dr. Ashish Sharma with us we will discuss some questions related to the study 1. How common are retinal diseases like diabetic macular edema and macular neovascularization? 2. How do the BCVA and CST improvements seen in the BRESER study reflect in daily practice? 3. Advice for young ophthalmologist on how to approach the use of biosimilars like Ranieyes 4. How do biosimilars like Ranieyes help in making treatment more affordable for patients in India? 5. Are more Indian real-world studies like BRESER important for doctors?